As foundations and governments mobilize to tackle antimicrobial resistance (AMR), several experiments in academic–industrial collaboration have emerged. Here, I examine two historical precedents, the Penicillin Project and the Malaria Project of the Second World War, and two contemporary examples, the Tuberculosis Drug Accelerator programme and the Tres Cantos Open Lab. These and related experiments suggest that different strategies can be effective in managing academic–industrial collaborations, and that such joint projects can prosper in both multisite and single-site forms, depending on the specific challenges and goals of each project. The success of these strategies and the crisis of AMR warrant additional investment in similar projects.
Your institute does not have access to this article
Open Access articles citing this article.
Biology Direct Open Access 14 October 2020
Scientific Reports Open Access 28 September 2016
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Nathan, C. & Cars, O. Antibiotic resistance—problems, progress, and prospects. New Engl. J. Med. 371, 1761–1763 (2014).
O'Neill, J. C. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance [online], (2014).
Nathan, C. Antibiotics at the crossroads. Nature 431, 899–902 (2004).
Lax, E. The Mould in Dr Florey's Coat: the Remarkable True Story of Penicillin (Little, Brown & Co., 2004).
Abraham, E. P. & Chain, A. Purification of penicillin. Nature 149, 328–328 (1942).
Abraham, E. P. et al. Further observations on penicillin. Lancet 238, 177–189 (1941).
Chain, E. et al. Penicillin as a chemotherapeutic agent. Lancet 236, 226–228 (1940).
Swann, J. P. The search for synthetic penicillin during World War II. Br. J. Hist. Sci. 16, 154–190 (1983).
Rasmussen, N. Of “small men”, big science and bigger business: the Second World War and biomedical research in the United States. Minerva 40, 115–146 (2002).
Brown, K. Penicillin Man: Alexander Fleming and the Antibiotic Revolution (Sutton Publishing, 2004).
Lockwood, J. S. War-time activities of the National Research Council and the Committee on Medical Research: with particular reference to team-work on studies of wounds and burns. Ann. Surg. 124, 314–327 (1946).
Keefer, C. S. et al. Penicillin in the treatment of infections. A report of 500 cases. JAMA 122, 1217–1224 (1943).
Richards, A. N. Penicillin. Statement released by the Committee on Medical Research. JAMA 122, 235–236 (1943).
Sheehan, J. C. & Henery-Logan, K. R. The total synthesis of penicillin V. J. Am. Chem. Soc. 79, 1262–1263 (1957).
Coggeshall, L. T. et al. Research work on chemotherapy. Science 192, 176–178 (1940).
Masterson, K. M. The Malaria Project: The U.S. Government's Secret Mission to Find a Miracle Cure (New American Library, 2014).
Slater, L. B. War and Disease (Rutgers Univ. Press, 2014).
Coatney, G. R. Pitfalls in a discovery: the chronicle of chloroquine. Am. J. Trop. Med. Hyg. 12, 121–128 (1963).
World Health Organization. Making a difference: 30 years of research and capacity building in tropical diseases. WHO [online], (2007).
Bathurst, I. & Hentschel, C. Medicines for Malaria Venture: sustaining antimalarial drug development. Trends Parasitol. 22, 301–307 (2006).
O'Brien, S. Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry. Br. J. Clin. Pharmacol. 79, 168–172 (2015).
Rex, J. H. ND4BB: addressing the antimicrobial resistance crisis. Nat. Rev. Microbiol. 12, 231–232 (2014).
Stavenger, R. A. & Winterhalter, M. TRANSLOCATION project: how to get good drugs into bad bugs. Sci. Transl. Med. 6, 228ed7 (2014).
Chakraborty, S. et al. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339, 88–91 (2013).
Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159–167 (2014).
Kim, J. H. et al. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc. Natl Acad. Sci. USA 110, 19095–19100 (2013).
Rottmann, M. et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175–1180 (2010).
Morel, C. M. & Mossialos, E. Stoking the antibiotic pipeline. BMJ 340, c2115 (2010).
Nathan, C. Aligning pharmaceutical innovation with medical need. Nat. Med. 13, 304–308 (2007).
Nathan, C. Fresh approaches to anti-infective therapies. Sci. Transl. Med. 4, 140sr2 (2012).
Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40 (2007).
Projan, S. J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427–430 (2003).
Van Boekel, T. P. et al. Global trends in antimicrobial use in food animals. Proc. Natl Acad. Sci. USA 112, 5649–5654 (2015).
The author thanks L. L. Tmanova (Wood Library, Weill Cornell Medical College, New York, USA) for assistance, and K. Rhee and K. Burns-Huang (Weill Cornell Medical College) for their comments. The Department of Microbiology and Immunology at Weill Cornell Medical College is supported by the William Randolph Hearst Foundation.
C.N. is a participant in the Tuberculosis Drug Accelerator (TBDA) (funded by the Bill & Melinda Gates Foundation) and a member of the Board of Governors of the Tres Cantos Open Lab Foundation.
About this article
Cite this article
Nathan, C. Cooperative development of antimicrobials: looking back to look ahead. Nat Rev Microbiol 13, 651–657 (2015). https://doi.org/10.1038/nrmicro3523
Biology Direct (2020)
Nature Reviews Microbiology (2020)
Scientific Reports (2016)